Cargando…

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes

AIMS: To analyse the effect of baseline glycated haemoglobin (HbA(1c)) on the reduction in HbA(1c) with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. MATERIALS AND METHODS: Using regression analyses of individual patient data from two Phase III studies, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeFronzo, Ralph A., Ferrannini, Ele, Schernthaner, Guntram, Hantel, Stefan, Elsasser, Ulrich, Lee, Christopher, Hach, Thomas, Lund, Søren S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354821/ https://www.ncbi.nlm.nih.gov/pubmed/30815552 http://dx.doi.org/10.1002/edm2.16

Ejemplares similares

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride
por: Chirila, Costel, et al.
Publicado: (2015)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks
por: Hamaguchi, Tomoya, et al.
Publicado: (2011)

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
por: Inzucchi, Silvio E., et al.
Publicado: (2020)

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
por: Leiter, Lawrence A., et al.
Publicado: (2016)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients
por: Bando, Yukihiro, et al.
Publicado: (2011)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
por: Jones, Angus G., et al.
Publicado: (2016)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2019)

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
por: Gallwitz, Baptist, et al.
Publicado: (2017)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
por: Ceriello, Antonio, et al.
Publicado: (2020)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats
por: Saad, Mohamed I., et al.
Publicado: (2015)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Influence of Baseline HbA1c and Antiplatelet Therapy on 1-Year Vein Graft Outcome
por: Zhu, Yunpeng, et al.
Publicado: (2022)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

The effects of early short-term insulin treatment vs. glimepiride on beta cell function in newly diagnosed type 2 diabetes with HbA1c above 9%
por: STOJANOVIC, Jelena, et al.
Publicado: (2023)

The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data
por: Ozcelik, Serhat, et al.
Publicado: (2019)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial
por: Fortin, Elena, et al.
Publicado: (2023)

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study
por: Tamura, Haruka, et al.
Publicado: (2022)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)
por: Kesavadev, Jothydev, et al.
Publicado: (2017)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bf70mf0j1d7pp565i58k0h6tg1